Aligos rises as mid‑stage trial for hepatitis B drug advances
21/01/2026 15:00
** Shares of biotech firm Aligos Therapeutics ALGS.O up 3% at $8.25 ** Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients ** Expects first interim data from study in early 2026, main results in 2027 ** ALGS says earlier tests showed the oral drug reduced infection markers ** Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway ** ALGS was down ~25% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue